Key result
Valvular heart disease was associated with an aggregated annual incremental direct healthcare expenditure of $56.62 billion, peaking at $30,949 per patient for those ≥75 years with symptomatic AVD.
Why the study?
The study was conducted to quantify healthcare expenditures for valvular heart disease in the USA.
What are the direct annual incremental healthcare expenditures associated with valvular heart disease in the USA?
Observational (n=1,463)
What are the direct annual incremental healthcare expenditures associated with valvular heart disease in the USA?
Valvular heart disease imposes a massive economic burden in the USA, particularly among elderly patients with symptomatic aortic valve disease, highlighting the potential economic value of earlier identification and treatment.
Answers are grounded in this paper and cite their sources.
Valvular disease drives high costs especially in elderly symptomatic patients; leaves open whether earlier detection reduces expenditures.
Aim: To quantify the healthcare expenditures for valvular heart disease (VHD) in the USA. Patients & methods: Direct annual incremental healthcare expenditures were estimated using multiple logistic and linear regression models. Results were stratified by age cohorts (18–64 years, ≥65 and ≥75 years) and disease status: symptomatic aortic valve disease (AVD), asymptomatic AVD, symptomatic mitral valve disease (MVD) and asymptomatic MVD. Results: A total of 1463 VHD patients were identified. The overall aggregated incremental direct expenditures were $56.62 billion ($26.48 billion for patients ≥75 years). Individuals ≥75 years with symptomatic AVD had the largest incremental effect on annual, per-patient healthcare expenditure of $30,949. The annualized incremental costs of VHD were greatest for individuals ≥75 years with AVD. Conclusion: Identification of VHD at an earlier stage may reduce the economic burden.
No takes yet. Share an insight, caveat, or question.
Mallow et al. (2019) conducted an observational in Valvular heart disease (n=1,463). Valvular heart disease was evaluated on Direct annual incremental healthcare expenditures. Valvular heart disease was associated with an aggregated annual incremental direct healthcare expenditure of $56.62 billion, peaking at $30,949 per patient for those ≥75 years with symptomatic AVD.
Synapse has enriched 10 related papers. Consider them for comparative context: